InMed Pharmaceuticals Inc. (NASDAQ:INM – Get Free Report) was the target of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 26,900 shares, a drop of 25.1% from the February 13th total of 35,900 shares. Currently, 3.8% of the company’s shares are sold short. Based on an average daily volume of 462,300 shares, the short-interest ratio is presently 0.1 days.
InMed Pharmaceuticals Trading Down 2.8 %
Shares of InMed Pharmaceuticals stock traded down $0.08 on Monday, hitting $2.74. 24,166 shares of the company traded hands, compared to its average volume of 228,398. The stock’s 50 day moving average price is $3.49 and its 200-day moving average price is $4.45. The company has a current ratio of 3.05, a quick ratio of 2.44 and a debt-to-equity ratio of 0.09. InMed Pharmaceuticals has a 52 week low of $2.41 and a 52 week high of $15.70. The company has a market cap of $3.31 million, a PE ratio of -0.20 and a beta of 0.18.
InMed Pharmaceuticals (NASDAQ:INM – Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($3.64) earnings per share for the quarter. InMed Pharmaceuticals had a negative net margin of 163.75% and a negative return on equity of 90.74%.
About InMed Pharmaceuticals
InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.
Read More
- Five stocks we like better than InMed Pharmaceuticals
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Can TikTok Stock Picks Really Make You Rich?
- 3 Ways To Invest In Coffee, Other Than Drinking It
- The “Quality” Rotation: Back to Basics Investing
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.